Skip to main content

Imatinib

A Review of its Use in Chronic Myeloid Leukaemia

Drugs volume 67, pages 299–320 (2007)Cite this article

Summary

Abstract

Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor used in the treatment of chronic myeloid leukaemia (CML). It is specifically designed to inhibit the breakpoint cluster region (BCR)-Abelson (ABL) fusion protein that results from the chromosomal abnormality known as the Philadelphia chromosome. CML is characterised by this abnormality, which leads to abnormalities of the peripheral blood and bone marrow including an increase in the number of granular leukocytes. Imatinib is approved in numerous countries worldwide for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase CML, Ph+ accelerated-phase or blast-crisis CML, and in patients with Ph+ chronic-phase CML who have failed to respond to interferon-α therapy. It is also indicated in paediatric patients with newly diagnosed Ph+ chronic-phase CML, in accelerated-phase or blast-crisis CML, or in chronic-phase CML after failure of interferon-α therapy or when the disease has recurred after haematopoietic stem cell transplantation (HSCT). Approved indications, however, may vary by country.

Imatinib is effective and generally well tolerated in patients with Ph+ CML. In patients with newly diagnosed chronic-phase CML, imatinib was more effective than interferon-α plus cytarabine in preventing progression of the disease and in achieving haematological and cytogenetic responses. Overall survival rates remain high after 5 years of follow-up, and historical comparisons with other treatments demonstrate improved overall survival with imatinib in the long term. Patients with accelerated-phase or blast-crisis CML, or those who have not responded to prior interferon-α therapy also benefit from imatinib treatment. Some patients become resistant or intolerant to imatinib therapy; management strategies to overcome these problems include dosage adjustment, other treatments, or combination therapy with imatinib and other agents. Allogeneic HSCT is currently the only potentially curative treatment, but it is associated with high rates of morbidity and mortality and is not suitable for all patients. The introduction of imatinib has had a marked impact on outcomes in patients with CML. It remains a valuable treatment for all stages of the disease, especially initial treatment of newly diagnosed Ph+ chronic-phase CML, and is endorsed by European and US treatment guidelines as a first-line option.

Pharmacological Properties

Imatinib inhibits BCR-ABL tyrosine kinase, which is expressed by CML cells with the Philadelphia chromosome abnormality. It also inhibits the receptor tyrosine kinases for platelet-derived growth factor and stem cell factor. Administration of imatinib to CML patients results in marked changes in bone marrow histopathology and normalisation of bone marrow vascularity in some patients.

Primary or acquired resistance to imatinib is common in patients with advanced CML. There are several mechanisms of resistance and most involve reactivation of BCR-ABL signalling. Serial measurements of BCR-ABL transcript levels and ABL mutational screening can help identify the presence of BCR-ABL tyrosine kinase domain mutations and thereby emerging resistance.

Following oral administration, imatinib is rapidly absorbed. The bioavailability of imatinib is 98%, and peak plasma concentrations are reached after 2–4 hours. Imatinib is metabolised by the liver and is primarily eliminated via the faeces as unchanged parent drug and metabolites.

Dosage adjustments are recommended in patients with severe hepatic dysfunction. Systemic exposure of imatinib may be altered when the drug is coadministered with various cytochrome P450 inducers or inhibitors.

Therapeutic Efficacy

In a randomised, nonblind, multicentre phase III trial in patients with newly diagnosed Ph+ chronic-phase CML, imatinib significantly improved the estimated rates of survival without progression and survival without progression to accelerated-phase or blast-crisis CML compared with interferon-α plus cytarabine at median follow-ups of 19 and 30 months. Haematological and cytogenetic responses were also significantly greater in the imatinib group at both follow-ups.

Rates of freedom from progression and haematological and cytogenetic response remained high in imatinib recipients at a 60-month follow-up of the phase III trial, although comparisons with interferon-α plus cytarabine recipients were not possible, as the majority of those randomised to interferon-α plus cytarabine had crossed over to the imatinib treatment arm.

For the same reason, a between-treatment group comparison of overall survival in the phase III study was not possible. In an historical comparison between different trials, overall survival rates at 36 months for imatinib recipients in the phase III trial were significantly higher than those for interferon-α plus cytarabine recipients in another study.

Imatinib also produced high rates of haematological and cytogenetic responses in phase II trials of Ph+ patients with accelerated-phase or blast-crisis CML, and in those who received second-line imatinib, with long-term follow-up (median 60 months), after failure of interferon-α therapy.

Cost-effectiveness analyses generally predict that imatinib is a costly, but generally cost-effective, treatment option; it is more effective and less costly than bone marrow transplantation.

Tolerability

Imatinib was generally well tolerated. Most imatinib recipients in the phase II and III studies experienced adverse events, usually of mild to moderate severity. The most common nonhaematological adverse events in patients with chronic-phase CML were superficial oedema, muscle cramps, diarrhoea, nausea and musculoskeletal pain. Similar tolerability profiles were seen in the phase II studies in patients with accelerated-phase or blast-crisis CML, and in those who had failed to respond to prior therapy with interferon-α.

Grade 3 or 4 neutropenia, thrombocytopenia and anaemia occurred in imatinib recipients in all phase II studies and in the phase III study, and appeared to be more severe in patients with advanced disease. In patients with chronic-phase CML in the phase III study, the incidences of grade 3 plus 4 neutropenia and thrombocytopenia were significantly lower in imatinib recipients than in those who received interferon-α plus cytarabine.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III
Fig. 1
Table IV
Fig. 2
Fig. 3
Table V

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001 Aug; 286: 895–8

    PubMed  Article  CAS  Google Scholar 

  2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000 Nov 15; 96 (10): 3343–56

    PubMed  CAS  Google Scholar 

  3. Knight GW, McLellan D. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia. Br J Biomed Sci 2004; 61 (2): 103–11

    PubMed  CAS  Google Scholar 

  4. Angstreich GR, Smith BD, Jones RJ. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant. Curr Opin Oncol 2004 Mar; 16 (2): 95–9

    PubMed  Article  Google Scholar 

  5. Curran MP, Croom KF, Goa KL. Imatinib mesylate: a review of its use in chronic myeloid leukemia. Am J Cancer 2003; 2 (6): 439–54

    Article  CAS  Google Scholar 

  6. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63 (5): 513–22

    PubMed  Article  CAS  Google Scholar 

  7. Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61 (12): 1765–74

    PubMed  Article  CAS  Google Scholar 

  8. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 Apr 1; 105 (7): 2640–53

    PubMed  Article  CAS  Google Scholar 

  9. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100–4

    PubMed  CAS  Google Scholar 

  10. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 May; 2 (5): 561–6

    PubMed  Article  CAS  Google Scholar 

  11. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997 Dec 15; 90: 4947–52

    PubMed  CAS  Google Scholar 

  12. Park J, Kim S, Oh C, et al. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate. Biochem Biophys Res Commun 2005 Oct 28; 336 (3): 942–51

    PubMed  Article  CAS  Google Scholar 

  13. le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999 Jan 20; 91 (2): 163–8

    PubMed  Article  Google Scholar 

  14. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295 (1): 139–45

    PubMed  CAS  Google Scholar 

  15. Uziel O, Fenig E, Nordenberg J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005 May 23; 92 (10): 1881–91

    PubMed  Article  CAS  Google Scholar 

  16. Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 2004 Jul 15; 104 (2): 495–501

    PubMed  Article  CAS  Google Scholar 

  17. Gottschalk S, Anderson N, Hainz C, et al. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004 Oct 1; 10 (19): 6661–8

    PubMed  Article  CAS  Google Scholar 

  18. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005 May; 46 (5): 540–50

    PubMed  Article  CAS  Google Scholar 

  19. Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 2004 May 1; 103 (9): 3549–51

    PubMed  Article  CAS  Google Scholar 

  20. Bueso-Ramos CE, Cortes J, Talpaz M, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004 Jul 15; 101 (2): 332–6

    PubMed  Article  CAS  Google Scholar 

  21. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75–85

    PubMed  Article  Google Scholar 

  22. Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months’ experience. Blood 2002 Jul 15; 100 (2): 435–41

    PubMed  Article  CAS  Google Scholar 

  23. Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002 Mar; 117 (3): 360–7

    PubMed  Article  CAS  Google Scholar 

  24. Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 2002 Oct; 119 (1): 3–14

    PubMed  Article  CAS  Google Scholar 

  25. Cortes J. Overcoming drug resistance in chronic myeloid leukemia. Curr Opin Hematol 2006 Mar; 13 (2): 79–86

    PubMed  Article  CAS  Google Scholar 

  26. Yin T, Wu YL, Sun HP, et al. Combined effects of AS4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 2004 Dec 15; 104 (13): 4219–25

    PubMed  Article  CAS  Google Scholar 

  27. Du Y, Wang K, Fang H, et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 2006 Feb 15; 107 (4): 1582–90

    PubMed  Article  CAS  Google Scholar 

  28. Jorgensen HG, Copland M, Allan EK, et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006 Jan 15; 12 (2): 626–33

    PubMed  Article  CAS  Google Scholar 

  29. Aloisi A, Di Gregorio S, Stagno F, et al. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 2006 Feb 15; 107 (4): 1591–8

    PubMed  Article  CAS  Google Scholar 

  30. Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw 2005 Nov; 3 (6): 757–68

    PubMed  Google Scholar 

  31. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006; 125: 93–106

    PubMed  CAS  Google Scholar 

  32. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 Aug 3; 293 (5531): 876–80

    PubMed  Article  CAS  Google Scholar 

  33. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 Mar 1; 95: 1758–66

    PubMed  Google Scholar 

  34. Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5 (1): 55–60

    PubMed  Article  CAS  Google Scholar 

  35. Larghero J, Leguay T, Mourah S, et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo. Biochem Pharmacol 2003 Nov 15; 66 (10): 1907–13

    PubMed  Article  CAS  Google Scholar 

  36. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 Acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003 Feb; 9 (2): 625–32

    PubMed  CAS  Google Scholar 

  37. Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 2005 Jan; 12 (1): 33–9

    PubMed  Article  CAS  Google Scholar 

  38. Wang L, Knight K, Lucas C, et al. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006 Feb; 91 (2): 235–9

    PubMed  CAS  Google Scholar 

  39. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004 Nov 1; 104 (9): 2926–32

    PubMed  Article  CAS  Google Scholar 

  40. Wang L, Pearson K, Pillitteri L, et al. Serial monitoring of BCR-ABL by peripheral blood real time polymerase chain reaction predicts the marrow cytogenic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771–7

    PubMed  Article  CAS  Google Scholar 

  41. Martinelli G, Iacobucci I, Rosti G, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol 2006 Mar; 17 (3): 495–502

    PubMed  Article  CAS  Google Scholar 

  42. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib-treated patients with CML. Blood 2006 Jun 1; 107 (11): 4250–6. Epub 2006 Feb 7

    PubMed  Article  CAS  Google Scholar 

  43. Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006 May 15; 12 (10): 3037–42

    PubMed  Article  CAS  Google Scholar 

  44. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005 Jun 20; 23 (18): 4100–9

    PubMed  Article  CAS  Google Scholar 

  45. Hughes T, Deininger M, Hochhaus A. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. 2006; 108 (1): 28–37

    CAS  Google Scholar 

  46. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44 (9): 879–94

    PubMed  Article  CAS  Google Scholar 

  47. Leveque D, Maloisel F. Clinical pharmacokinetics of imatinib mesylate. In Vivo 2005; 19 (1): 77–84

    PubMed  CAS  Google Scholar 

  48. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005 Oct; 33 (10): 1503–12

    PubMed  Article  CAS  Google Scholar 

  49. Novartis Pharmaceuticals Corporation. Prescribing information (US): Gleevec® (imatinib mesylate) tablets [online]. Available from URL: http://www.fda.gov/cder [Accessed 2007 Jan 16]

  50. Novartis Europharm Limited. Prescribing information (EU): Glivec® (imatinib mesylate) tablets [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/glivec/glivec.htm [Accessed 2007 Jan 17]

  51. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004 Mar 1; 22 (5): 935–42

    PubMed  Article  CAS  Google Scholar 

  52. O’Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003 Nov 17; 89 (10): 1855–9

    PubMed  Article  Google Scholar 

  53. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 Mar 13; 348 (11): 994–1004

    PubMed  Article  Google Scholar 

  54. Druker BJ, Guilhot F, O’Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med 2006; 355 (23): 2408–17

    Article  CAS  Google Scholar 

  55. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002 Mar 15; 99 (6): 1928–37

    PubMed  Article  CAS  Google Scholar 

  56. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002 May 15; 99 (10): 3530–9

    PubMed  Article  CAS  Google Scholar 

  57. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 Feb 28; 346 (9): 645–52

    PubMed  Article  CAS  Google Scholar 

  58. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group phase 1 study. Blood 2004 Nov 1; 104 (9): 2655–60

    PubMed  Article  CAS  Google Scholar 

  59. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006 Feb; 20 (2): 187–92

    PubMed  Article  CAS  Google Scholar 

  60. Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004 Apr 15; 103 (8): 2873–8

    PubMed  Article  CAS  Google Scholar 

  61. Cortes J, Giles F, O’Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-postive chronic myeloid leukemia after failure of interferon-α. Blood 2003 Jul 1; 102 (1): 83–6

    PubMed  Article  CAS  Google Scholar 

  62. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003 Jun 1; 21 (11): 2138–46

    PubMed  Article  CAS  Google Scholar 

  63. Goldman JM, Hughes T, Radich J, et al. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS study [abstract no. 163]. Blood 2005 Nov 16; 106 (11): 51a

    Google Scholar 

  64. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 Apr 5; 344 (14): 1031–7

    PubMed  Article  CAS  Google Scholar 

  65. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract no. 23]. Blood 2004 Nov 16; 104 (11 Pt 1): 11a. Plus oral presentation presented at the 46th Annual Meeting and Exposition of the American Society of Hematology; 2004 Dec 3–7; San Diego (CA)

  66. Kantarjian HM, Sawyers C, Hocchaus A, et al. Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) Chronic Myeloid Leukemia (CML) post interferon-alpha (IFN) [abstract no. 428]. Blood 2006 Nov; 108 (11): 130–1

    Google Scholar 

  67. Van Hoomissen IC, Hensley ML, Krahnke T, et al. Imatinib expanded access program (EAP): results of treatment in >7000 patients with chronic myeloid leukemia (CML) [abstract no. 3370]. Blood 2003 Nov 16; 102 (11 Pt 1): 906a

    Google Scholar 

  68. Kantarjian HM, O’Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002 Jul; 8 (7): 2167–76

    PubMed  CAS  Google Scholar 

  69. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006 Sep 1; 108 (5): 1478–84

    PubMed  Article  CAS  Google Scholar 

  70. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997 Jul 24; 337 (4): 223–9

    CAS  Google Scholar 

  71. Kantarjian H, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer 2005 May 15; 103 (10): 2099–108

    PubMed  Article  CAS  Google Scholar 

  72. Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002 May 15; 99 (10): 3547–53

    PubMed  Article  CAS  Google Scholar 

  73. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006 Aug; 12 (8): 908–16

    PubMed  Article  Google Scholar 

  74. Hatfield A, Owen S, Pilot PR. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’ [letter]. Nat Med 2007 Jan; 13 (1): 13

    PubMed  Article  CAS  Google Scholar 

  75. Force T. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’ [letter]. Nat Med 2007 Jan; 13 (1): 15–6

    Article  CAS  Google Scholar 

  76. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006 May 11; 354 (19): 2006–13

    PubMed  Article  CAS  Google Scholar 

  77. Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005; 23 (5): 515–26

    PubMed  Article  CAS  Google Scholar 

  78. Warren E, Ward S, Gordois A, et al. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther 2004 Nov; 26 (11): 1924–33

    PubMed  Article  Google Scholar 

  79. Gordois A, Scuffham P, Warren E, et al. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer 2003 Aug 18; 89 (4): 634–40

    PubMed  Article  CAS  Google Scholar 

  80. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004 Dec 1; 101 (11): 2574–83

    PubMed  Article  Google Scholar 

  81. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005 Mar; 25 (3): 325–34

    PubMed  Article  Google Scholar 

  82. Groot MT, Anstrom KD, Reed SD, et al. Cost-effectiveness of imatinib versus interferon (IFN-α) plus low-dose cytarabine (ARA-C) for newly diagnosed chronic phase chronic myeloid leukemia (CML) in the The Netherlands [abstract no. CN3]. Value Health 2004; 7 (6): 644. Plus oral presentation presented at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2004 Oct 24–26; Hamburg

    Article  Google Scholar 

  83. Simonsson B, Kloke O, Stahel RA. ESMO minimum clinical recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). ESMO Guidelines Task Force. Ann Oncol 2005; 16 Suppl. 1: i52–3

    PubMed  Article  Google Scholar 

  84. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia v.2.2007 [online]. Available from URL: http://www.nccn.org [Accessed 2007 Jan 17]

  85. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 Sep 15; 108 (6): 1809–20

    PubMed  Article  CAS  Google Scholar 

  86. Nadal E, Olavarria E. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. Int J Clin Pract 2004 May; 58 (5): 511–6

    PubMed  Article  CAS  Google Scholar 

  87. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004; 9 (3): 271–81

    PubMed  Article  CAS  Google Scholar 

  88. Bristol-Myers Squibb Company. Prescribing information (US): Sprycel™ (dasatinib) tablets [online]. Available from URL: https://www.sprycel.com/ [Accessed 2006 Nov 23]

  89. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology (Am Soc Hematol Educ Program) 2005, 183–7

  90. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 Jun 15; 354 (24): 2542–51

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Wolters Kluwer Health / Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Marit D. Moen, Kate McKeage, Greg L. Plosker & M. Asif A. Siddiqui

Authors
  1. Marit D. Moen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Asif A. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Asif A. Siddiqui.

Additional information

Various sections of the manuscript reviewed by: E. Berman, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; C. Gambacorti-Passerini, Department of Clinical and Preventive Medicine, University of Milano Bicocca, Milan, Italy; J.H. Goldman, Haematology Department, Hammersmith Hospital/Imperial College, London, England; A. Hochhaus, III Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany; R.A. Larson, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA; G. Rosti, Institute of Hematology and Medical Oncology ‘Seragnoli’, St. Orsola Hospital-Bologna University, Bologna, Italy; B. Simonsson, Department of Hematology, University Hospital, Uppsala University, Uppsala, Sweden.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘imatinib’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘imatinib’ and (‘CML’ or ‘chronic myeloid leukaemia’). Searches were last updated 18 January 2007.

Selection: Studies in patients with chronic myeloid leukaemia who received imatinib. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Imatinib, imatinib mesylate, chronic myeloid leukaemia, chronic myelogenous leukaemia, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moen, M.D., McKeage, K., Plosker, G.L. et al. Imatinib. Drugs 67, 299–320 (2007). https://doi.org/10.2165/00003495-200767020-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767020-00010

Keywords

  • Imatinib
  • Chronic Myeloid Leukaemia
  • Haematopoietic Stem Cell Transplantation
  • Chronic Myeloid Leukaemia Patient
  • Cytogenetic Response